Date | Time | Source | Headline | Symbol | Company |
05/29/2024 | 8:00AM | GlobeNewswire Inc. | Tevogen Bio Reports First Quarter 2024 Financial Results | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
05/16/2024 | 2:00PM | GlobeNewswire Inc. | Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
05/10/2024 | 5:40PM | GlobeNewswire Inc. | Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
05/01/2024 | 8:05AM | GlobeNewswire Inc. | Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
04/26/2024 | 9:23AM | GlobeNewswire Inc. | Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
04/11/2024 | 8:05AM | GlobeNewswire Inc. | Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
04/03/2024 | 8:05AM | GlobeNewswire Inc. | Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
03/28/2024 | 8:05AM | GlobeNewswire Inc. | Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
03/20/2024 | 7:00AM | Business Wire | Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
03/05/2024 | 8:00AM | Business Wire | Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
03/04/2024 | 4:24PM | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/27/2024 | 4:39PM | Business Wire | Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/22/2024 | 8:13PM | Edgar (US Regulatory) | Form SC 13D - General statement of acquisition of beneficial ownership | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/22/2024 | 8:09PM | Edgar (US Regulatory) | Form SC 13D - General statement of acquisition of beneficial ownership | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/21/2024 | 4:30PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/21/2024 | 7:00AM | Business Wire | Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/20/2024 | 8:57AM | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/17/2024 | 12:17AM | Business Wire | Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/16/2024 | 5:30PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/16/2024 | 5:29PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/16/2024 | 5:28PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/16/2024 | 5:28PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/16/2024 | 5:26PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/16/2024 | 5:26PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/16/2024 | 5:25PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/16/2024 | 5:24PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/16/2024 | 5:20PM | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/16/2024 | 5:19PM | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/16/2024 | 5:17PM | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:TVGN | Tevogen Bio Holdings Inc |
02/16/2024 | 5:15PM | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:TVGN | Tevogen Bio Holdings Inc |